Abstract
Acetyl salicylic acid (ASA), a non-steroidal anti-inflammatory drug, was formulated into inclusion complexes by grinding and precipitation with β-cyclodextrin and freeze drying with pyromellitic dianhydride (PMDA) cross-linked β-cyclodextrin nanosponges. Particle size, zeta potential, encapsulation efficiency, accelerated stability study, in vitro and in vivo release studies were used as characterization parameters. TEM studies showed that the particle sizes of different inclusion complexes of ASA have diameters ranging from 40.12 ± 8.79 to 59.53 ± 15.55 nm. It also revealed the regular spherical shape and sizes of complexes that are even unaffected after drug encapsulation. Zeta potential was sufficiently high to obtain a stable colloidal formulation. The in vitro and in vivo studies indicated a slow and prolonged ASA release from PMDA cross-linked β-cyclodextrin nanosponges over a long period. XRPD, DSC and FTIR studies confirmed the interactions of ASA with nanosponges. XRPD showed the crystalline nature of ASA decreased after encapsulation. These results indicate that ASA nanosponges formulation can be used for oral delivery.
Similar content being viewed by others
References
Torne, S., Ansari, A., Vavia, R., Trotta, F., Cavalli, R.: Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv. 17, 419–442 (2010)
Swaminathan, S., Cavalli, R., Trotta, F., Ferruti, P., Ranucci, E., Gerges, I., Manfredi, A., Marinotto, D., Vavia, P.: In vitro release modulation and conformational stabilization of a model protein using swellable polyamidoamine nanosponges of β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem 68, 183–191 (2010)
Ansari, K., Vavia, P., Trotta, F., Cavalli, R.: Cyclodextrin-based nanosponges for delivery of resveratrol: In vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech 12, 1 (2011)
Cavalli, R., Trotta, F., Tumiatti, W.: Cyclodextrin-based nanosponges for drug delivery. J. Incl. Phenom. Macrocycl. Chem. 56, 209–213 (2006)
Swaminathan, S., Pastero, L., Serpe, L., Trotta, F., Vavia, P., Aquilano, D., Trotta, M., Zara, G., Cavalli, R.: Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. Eur. J. Pharm. Biopharm. 74, 193–201 (2010)
Patel, D., Hesse, A., Ogunbona, A., Notarianni, L., Bennett, P.: Metabolism of aspirin after therapeutic and toxic doses. Hum. Exp. Toxicol. 9, 131–136 (1990)
Vane, J., Bottin, R.: The mechanism of action of aspirin. Thromb. Res. 110, 255–258 (2003)
El-Gendy, G., Terada, K., Yamamoto, K., Nakai, Y.: Molecular behavior, dissolution characteristics ‘and chemical stability of aspirin in the ground mixture and in the inclusion complex with di-0-methyl-/3-cyclodextrin. Int. J. Pharm. 31, 25–31 (1986)
Szejtli, J.: Cyclodextrin technology, p. 280. Kluwer, Dordrecht (1988)
Mannila, J., Jarvinen, T., Jarvinen, K., Jarho, P.: Precipitation complexation method produces cannabidiol/b-cyclodextrin inclusion complex suitable for sublingual administration of cannabidio. J. Pharm. Sci. 96, 312–319 (2007)
Trotta, F., Tumiatti, W., Vallero, R.: Italian Patent No. MI2004 A000614
Mele, A., Castiglione, F., Malpezzi, L., Ganazzoli, F., Raffaini, G., Trotta, F., Rossi, B., Fontana, A., Giunchi, G.: HR MAS NMR, powder XRD and Raman spectroscopy study of inclusion phenomena in β-CD nanosponges. J. Incl. Phenom. Macrocycl. Chem. 69, 403–409 (2011)
Shende, P., Gaud, R.: Formulation and comparative characterization of chitosan, gelatin, and chitosan–gelatin-Coated Liposomes of CPT-11–HCl. Drug Dev. Ind. Pharm. 35, 612–618 (2009)
Organization of Economic Co-operation Development: The OECD guidelines for testing of chemicals, 423. Acute oral toxicity test, Paris (2001)
Kulkarni, Y., Gokhale, S., Veeranjaneyulu, A., Surana, S., Tatiya, A.: Effect of Persea macrantha against acute inflammation and adjuvant-induced arthritis in rats. Pharm Biol. 47, 304–308 (2009)
Das, S., Banerjee, R., Bellar, J.: Aspirin loaded albumin nanoparticles by coacervation: implications in drug delivery. Trends Biomater. Artif. Organs 18, 203–212 (2005)
Shekh, I., Gupta, V., Jain, A., Gupta, N.: Preparation and characterisation of B cyclodextrin aspirin inclusion complex. Int. J. Pharm. Life Sci. 2, 704–710 (2011)
Nishioka, F., Nakanishi, I., Fujiwara, T., Tomita, K.: The crystal and molecular structure of the β-cyclodextrin inclusion complex with aspirin and salicylic acid. J. Incl. Phenom. Macrocycl. Chem. 2, 701–714 (1984)
Loftsson, T., Ólafsdóttir, B., Friðriksdóttir, H., Jónsdóttir, S.: Cyclodextrin complexation of NSAIDSs: physicochemical characteristics. Eur. J. Pharm. Sci. 1, 95–101 (1993)
Boyd, E.: The acute oral toxicity of acetylsalicylic acid. Toxicol. Appl. Pharmacol. 1, 229–239 (1959)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shende, P.K., Trotta, F., Gaud, R.S. et al. Influence of different techniques on formulation and comparative characterization of inclusion complexes of ASA with β-cyclodextrin and inclusion complexes of ASA with PMDA cross-linked β-cyclodextrin nanosponges. J Incl Phenom Macrocycl Chem 74, 447–454 (2012). https://doi.org/10.1007/s10847-012-0140-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10847-012-0140-x